Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 273-234-6 | CAS number: 68953-96-8 This substance is identified by SDA Substance Name: C11-C13 branched alkyl benzene sulfonic acid calcium salt and SDA Reporting Number: 25-097-06.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The acute toxicity of Branched CaDDBS via oral and dermal exposures was evaluated in rats. The acute oral LD50 was >2000 mg/kg bw. The acute dermal LD50 was between 1000 and 1600 mg/kg bw (Geometric mean = 1265 mg/kg bw).
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 1 265 mg/kg bw
Additional information
Two acute toxicity studies are available.
In the first, Branched CaDDBS (Phenylsulfonat CA) was given by gavage to male and female Wistar rats at a limit dose of 2000 mg/kg bw. No mortality or other toxic symptoms were observed. No effects on body weight gain were observed. The animals sacrificed at the end of the observation period showed no macroscopically visible changes. The resultant acute oral LD50 is >2000 mg/kg bw.
The acute dermal toxicity of Branched CaDDBS (Phenylsulfonat CA) was tested in male and female Wistar rats at doses of 1000, 1600 and 2000 mg/kg bw. Lethality was observed in the 1600 and 2000 mg/kg bw doses but not in the 1000 mg/kg bw dose. All lethality had occurred by day three of the post application observation period. Other signs of toxicity included impairments of respiration, motility and reflexes, as well as stupor, prone position, trembling, hypothermia, narrowed palpebral fissures, and blood-encrusted snouts, all of which had disappeared by eight days post application. The skin showed erythema, fine and coarse scales, desquamations and scars, as well as discoloration, induration, chapping, scabbing and lumpiness. No effects on body weight gain were observed. The resultant acute dermal LD50 is >1000 and <1600 mg/kg bw. The geometric mean of 1265 mg/kg bw is used as the key value.
Justification for selection of acute toxicity – oral endpoint
No mortality or other toxic symptoms were observed. No effects on body weight gain were observed. The animals sacrificed at the end of the observation period showed no macroscopically visible changes. The resultant acute oral LD50 is >2000 mg/kg bw.
Justification for selection of acute toxicity – inhalation endpoint
In accordance with Column 2 of Annex VIII-IX, in addition to the oral route, for substances other than gases, an acute toxicity study for one other route is required. The choice of the second route will depend on the nature of the substance and the likely route of exposure. As dermal is the most likely route of exposure and acute dermal toxicity data are available, no inhalation study need be conducted.
Justification for selection of acute toxicity – dermal endpoint
Lethality was observed in the 1600 and 2000 mg/kg bw doses but not in the 1000 mg/kg bw dose. All lethality had occurred by day three of the post application observation period. Other signs of toxicity included impairments of respiration, motility and reflexes, as well as stupor, prone position, trembling, hypothermia, narrowed palpebral fissures, and blood-encrusted snouts, all of which had disappeared by eight days post application. The skin showed erythema, fine and coarse scales, desquamations and scars, as well as discoloration, induration, chapping, scabbing and lumpiness. No effects on body weight gain were observed. The resultant acute dermal LD50 is >1000 and <1600 mg/kg bw.
Justification for classification or non-classification
No acute oral toxicity was observed so Branched CaDDBS is not classified under the DSD or CLP. Dermal values would result in classification as R21 under the DSD and Category 4 (H312) under the CLP.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.